HIGHLIGHTS
- What: The aim of this study is to gain novel understanding of the excretion of 131I in DTC patients by investigating whether there is a relationship between patients` clinical characteristics and the Teff of 131I. In the study the dose-rate data were collected during isolation period, mostly within the first 48 h after RAI administration.
- Who: Laura Kääriä and collaborators from the Department of Clinical Physiology, University Hospital and Wellbeing Turku, Finland have published the article: EJNMMI Physics Determination of effective half-life of 131I in thyroid cancer patients using remote doserate meter . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.